Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC

NCT02576574 is registered in ClinicalTrials.gov with EMD Serono Research & Development Institute, Inc. as lead sponsor.

NCT NCT02576574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02576574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Phase
Phase 3
Overall status
Completed
Start date
October 29, 2015
Completion date
January 29, 2024
Enrollment
1,214 (actual)
Sites
349

Conditions

As the registry lists them; a condition with its own page is linked.

first line non-small cell lung cancer